Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China
- 34 Downloads
Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) that is administered subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted dose of 100 µg/kg or as a 6 mg fixed dose. It is approved in China to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapy associated with a clinically significant incidence of febrile neutropenia. In phase III trials, once per cycle prophylaxis with mecapegfilgrastim was more effective than placebo in reducing the incidence of grade ≥ 3 neutropenia in cycle 1 in patients with advanced non-small cell lung cancer and was more effective than filgrastim at reducing the mean duration of grade ≥ 3 neutropenia in cycle 1 in patients with breast cancer. The tolerability and safety profiles of mecapegfilgrastim were similar to those of filgrastim, with no unexpected adverse events (AEs); most adverse reactions in cycle 1 were mild or moderate in severity. Thus, mecapegfilgrastim is an effective and generally well tolerated treatment option for patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, and extends the options available for managing chemotherapy-induced neutropenia in China.
The manuscript was reviewed by: C. Cerchione, Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy; P. Gascón, Division of Medical Oncology, Hospital Clinic, University of Barcelona, Barcelona, Spain. During the peer review process, the manufacturer of mecapegfilgrastim was also offered an opportunity to review this article. Changes resulting from comments received will be made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Zaina T. Al-Salama and Susan J. Keam are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
- 2.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid growth factors (version 2.2018). 2018. http://www.nccn.org. Accessed 23 Jul 2019.
- 6.Jiangsu Hengrui Pharma Inc. Mecapegfilgrastim: prescribing information [English translation]. Lianyungang City: Jiangsu Hengrui Pharma Inc. 2018.Google Scholar
- 8.Zhou C, Huang Y, Wang D, et al. A randomized multicenter phase III study of single administration of mecapegfilgrastim (HHPG-19K), a pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2016;17(2):119–27.CrossRefGoogle Scholar
- 11.Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.CrossRefGoogle Scholar
- 15.Ye X, Zhai Q, Wang Z-Y, et al. Neutropenic complications in Chinese patients with breast cancer in a real-world setting. Int J Clin Exp Pathol. 2017;10(1):651–60.Google Scholar
- 16.Kyowa Hakko Kirin Co. L. Products: GRAN®/ PEGLASTA® /Neulasta®. http://www.kyowa-kirin.com/. Accessed 23 Jul 2019.
- 17.Jefferies Financial Group. Pharmaceuticals: all about earnings; set to diverge. 2017. http://www.jefferies.com/CMSFiles/Jefferies.com/files/Insights/PharmaceuticalsAllAboutEarnings.pdf. Accessed 23 Jul 2019.
- 19.Shi YK, Chen Q, Zhu YZ, et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs. 2013;24(6):641–7.Google Scholar
- 21.Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31.CrossRefGoogle Scholar
- 23.Data on file, Qilu Pharma, 2019.Google Scholar
- 24.Amgen Inc. Neulasta® (pegfilgrastim) injection, for subcutaneous use: US prescribing information. 2019. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf. Accessed 23 Jul 2019.